- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Spigel on Adjuvant Chemotherapy in Stage IA/IIA, Molecularly Higher-Risk NSCLC
June 1st 2025, 4:53pm
Sarah Cannon Research Institute
David Spigel, MD, discusses evaluating the utility of adjuvant chemotherapy in patients with stage IA to IIA NSCLC identified as high risk by a 14-gene molecular assay.
Indirect Comparisons Shows Relatlimab/Nivolumab Has Comparable Outcomes to Ipilimumab/Nivolumab in Advanced Melanoma
June 1st 2025, 4:37pm
The efficacy of relatlimab/nivolumab was consistent across patient subgroups vs ipilimumab/nivolumab in advanced melanoma.
Sintilimab/Chidamide Plus P-GemOx Shows Antitumor Activity in Treatment-Naive, Early-Stage Natural Killer/T-Cell Lymphoma
June 1st 2025, 4:16pm
Sintilimab/chidamide followed by P-GemOx demonstrated preliminary efficacy in treatment-naive, early-stage extranodal natural killer/T-cell lymphoma.
Adagrasib Plus Pembrolizumab Generates Responses in KRAS G12C+ NSCLC
June 1st 2025, 3:41pm
Adagrasib plus pembrolizumab was efficacious in patients with KRAS G12C-mutant NSCLC.
Preoperative PAXG Extends EFS in Resectable and Borderline Resectable Pancreatic Cancer
June 1st 2025, 2:00pm
Neoadjuvant therapy with PAXG chemotherapy prolonged event-free survival vs mFOLFIRINOX in patients with stage I to III pancreatic ductal adenocarcinoma.
Adjuvant Nivolumab Generates Long-Term DFS Benefit in Resected Esophageal/GEJ Cancer
June 1st 2025, 1:50pm
Adjuvant nivolumab generated durable DFS and DMFS outcomes in resectable esophageal or GEJ cancer.
Addition of TTFields to Gemcitabine/Nab-Paclitaxel Boosts OS in Locally Advanced PDAC
June 1st 2025, 12:19pm
TTFields plus chemotherapy improved overall survival in unresectable, locally advanced pancreatic ductal adenocarcinoma.
Adjuvant Atezolizumab Plus mFOLFOX6 Improves DFS in dMMR Colon Cancer
June 1st 2025, 12:00pm
Adjuvant atezolizumab plus mFOLFOX6 improved disease-free survival vs mFOLFOX6 alone in patients with stage III, mismatch repair–deficient colon cancer.
Early Switch With Camizestrant Plus Continued CDK4/6 Inhibition Nearly Doubles PFS in ESR1-Mutant, ER+/HER2– Advanced Breast Cancer
June 1st 2025, 12:00pm
Emergent ESR1-mutant, ER-positive, HER2-negative advanced breast cancer was best treated with camizestrant and continued CDK4/6 inhibition vs SOC therapy.
Perioperative Durvalumab Plus FLOT Represents New SOC in Resectable Gastric/GEJ Adenocarcinoma
June 1st 2025, 12:00pm
The addition of durvalumab to perioperative FLOT improved event-free survival in resectable gastric/GEJ adenocarcinoma.
Postoperative Nivolumab Plus SOC Extends DFS in Resected, High-Risk Head and Neck Cancer
June 1st 2025, 12:00pm
Patients with locally advanced, high-risk head and neck cancer showed significantly improved DFS with adjuvant nivolumab plus cisplatin and radiotherapy.
NAPOLI-3 Analysis Exposes Characteristics of Long-Term PDAC Survivors Treated With NALIRIFOX
June 1st 2025, 1:26am
A post hoc analysis of NAPOLI-3 reveals insights on long-term survivors with pancreatic cancer who received NALIRIFOX.
First-Line Fruquintinib Combo May Offer New Treatment Strategy in ESCC
June 1st 2025, 1:05am
A fruquintinib regimen appeared safe and effective when used as a frontline treatment in esophageal squamous cell carcinoma.
T-DXd Maintains Efficacy in HR+/HER2-Low or HER2-Ultralow Breast Cancer Irrespective of Mutational Subtype
June 1st 2025, 12:07am
T-DXd maintained efficacy in HR-positive, HER2-low or -ultralow metastatic breast cancer irrespective of mutational subtype.
Ipatasertib Plus Fulvestrant Demonstrates Significant PFS Benefit in ER+/HER2– Metastatic Breast Cancer
May 31st 2025, 11:55pm
Ipatasertib plus fulvestrant extended PFS vs placebo plus fulvestrant in patients with ER-positive/HER2-negative metastatic breast cancer.
Dr Powles on EFS With Sasanlimab Plus BCG in BCG-Naive, High-Risk NMIBC
May 31st 2025, 11:18pm
Thomas Powles, MD, MBBS, MRCP, shares data from an EFS subgroup analysis from the phase 3 CREST study in BCG-naive, high-risk NMIBC.
Sasanlimab Plus BCG Displays EFS Benefit Across Key Subgroups in High-Risk Non–Muscle Invasive Bladder Cancer
May 31st 2025, 11:14pm
Sasanlimab plus BCG led to a PFS benefit vs BCG alone in patients with CIS and T1 high-risk non–muscle invasive bladder cancer.
Amivantamab Plus Chemo Maintains PFS Benefit in EGFR+ NSCLC Regardless of Osimertinib Resistance Mechanism
May 31st 2025, 11:08pm
Amivantamab/chemotherapy demonstrated sustained efficacy, despite the osimertinib resistance mechanism in patients with EGFR-mutated NSCLC.
Zanubrutinib Plus Venetoclax Yields High Response Rates in Treatment-Naive CLL/SLL
May 31st 2025, 10:00pm
Zanubrutinib in combination with venetoclax was highly active in patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Dr Picozzi on the Addition of TTFields to Gemcitabine and Nab-Paclitaxel in Locally Advanced PDAC
May 31st 2025, 9:42pm
Vincent Picozzi, MD, discusses the addition of TFields to gemcitabine and nab-paclitaxel in locally advanced pancreatic ductal adenocarcinoma.